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BY-NC-ND license (http://creativecomAbstract Arsenic is a well-known toxic element and carcinogenic agent. The aim of this study
was to investigate p63, E-cadherin, and b-catenin proteins in urothelial carcinoma (UC) in both
arsenic contaminated areas [so-called blackfoot disease (BFD) area] and non-BFD areas. The
expressions of p63, E-cadherin, and b-catenin proteins in 20 UC cases of blackfoot disease
and 22 UC cases in non-BFD areas were detected using immunohistochemical methods. The re-
sults revealed a high p63 expression in 20 (47.6%) UC cases and high E-cadherin expression in
six (14.3%) UC cases. Expressions of p63 and E-cadherin showed no significant correlations with
clinicopathologic parameters. However, all 20 BFD cases and 12 of 22 (54.5%) non-BFD cases
showed aberrant b-catenin expression. Ten out of 22 (45.5%) non-BFD cases also had normal
membranous immunoreactivity. The b-catenin staining pattern significantly differed between
cases in endemic and nonendemic areas of BFD (pZ 0.001). Tumor sites also significantly
correlated with b-catenin expression (pZ 0.044). In addition, membranous localization of b-
catenin was lower in UC from BFD-endemic areas compared with those from non-BFD endemic
areas. In conclusion, it is suggested that relocalization of b-catenin from membrane to cyto-
plasm may be involved in the tumorigenesis of UC from BFD-endemic areas.
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Arsenic is a widely distributed environmental metalloid
element that is carcinogenic in living organisms. Many
studies indicate that the toxic and carcinogenic effects of
arsenic can induce tumors. In Taiwan, the potential routes
of arsenic exposure include direct contact and consump-
tion of arsenic-contaminated food or water. Inorganic
arsenic compounds are also among the most potent human
carcinogens. Many animal studies and human studies indi-
cate that inorganic arsenic toxins (e.g., As2O3) can affect
internal organs, such as the liver, nervous system, cardio-
vascular system, or urinary system [1]. Long-term exposure
can cause chromosomal abnormalities, oxidative stress,
and altered signal transduction, all of which can cause
various forms of cancer [2]. Many Taiwanese studies have
reported an increased risk of cancer in people exposed to
arsenic through contaminated soil and well water [3e6].
The p63 gene is located on chromosome 3q27e28,
whose protein is a member of the p53 gene family. Both
have high sequence homology and share the same trans-
activation domain [7]. Under normal physiological condi-
tions, p63 expression is high in human epithelial cells and
in basal and intermediate cell layers of squamous and
transitional epithelium [8]. Because it controls and regu-
lates downstream-signaling cascade expression, the p63
gene has important roles in embryonic development, cell
adhesion, carcinogenesis, and transcriptional activity.
Indeed, studies of human tumors and mouse models have
shown that p63 has roles in both tumor development and
suppression [9]. Arsenic is known to decrease cell survival
by suppressing expression of protein p63 [10]. In WPE-stem
cells, p63 expression is also associated with maintenance
and self-renewal after arsenic-induced malignant trans-
formation [11]. Our earlier study also found that arsenic
induces mutant p53 protein expression in SV-40 immortal-
ized human uroepithelial cells [12]. However, the effects
of arsenic exposure on p63 expression have not been
compared between urothelial carcinoma (UC) cases in
endemic and no-endemic areas of blackfoot disease (BFD).
E-cadherin has crucial roles in assisting epithelial adhesion
and maintaining the integrity of tissue architecture. The
members of the cadherin family vary by location. For
example, E-cadherin is found in the membrane of normal
epithelial tissue, N-cadherin is found in neural epithelium,
and P-cadherin is found in the placenta [13]. Reduced E-
cadherin expression can cause loss of contact inhibition,
abnormal expression of growth regulators, and differenti-
ation and transformation of normal cells into malignant
cells. In patients with bladder tumors, downregulated E-
cadherin is associated with a poor prognosis [14]. By
contrast, E-cadherin and b-catenin are related to p63, and
abnormalities in their expressions are believed to be
associated with tumor development [15].
The multifunctional protein b-catenin, which is encoded
by the CTNNB1 gene in humans and is a subunit of the
cadherin protein complex, plays important roles in cellecell
adhesion and gene transcription. Free b-catenin in cyto-
plasm causes proteasome-mediated degradation of pro-
teins. During tumorigenesis, when E-cadherin expression on
cell surfaces is decreased or when proteasomal degradationPlease cite this article in press as: Chen Y-T, et al., Aberrant b-catenin
areas, Kaohsiung Journal of Medical Sciences (2016), http://dx.doi.orof cytosolic b-catenin is inhibited, b-catenin in cytoplasm
accumulates and then migrates into the nucleus. Interaction
between b-catenin in the nucleus and downstream tran-
scription factors causes abnormal activations of downstream
genes [16]. Mutations and overexpression of b-catenin are
associated with a poor prognosis in many cancers, such as
bladder cancer, hepatocellular carcinoma, and colorectal
cancer. Many reports indicate that b-catenin acts as a Wnt/
Wg signal transducer in cancer and embryogenesis [17,18].
The main purpose of this study was to observe the
expression of p63, E-cadherin, and b-catenin in UC and to
compare correlations between UC cases in endemic and
nonendemic areas of BFD.
Methods
Study cases and clinical data collection
This study included 42 cases of UC diagnosed in Kaohsiung
Medical University Hospital, Kaohsiung, Taiwan between
1991 and 2000. All clinical data were obtained by records
reviews, including sex, age, residency, tumor location, and
bladder recurrent status. BFD areas are located in the
southwestern townships of Taiwan, including Peimen,
Hsuechia, Putai, and Ichu, where the residents of the
village have drunk well water with a high arsenic content
for a long time.
All specimens were processed according to standard
pathologic procedures. After staining with hematoxylin and
eosin, all specimens were examined by an experienced
pathologist to confirm histological diagnosis and to assess
tumor grade and invasiveness according to the World Health
Organization system published in 2006 and the American
Joint Committee on cancer staging manual system pub-
lished in 2010. All tissue specimens were obtained with
permission from the Institutional Review Board of Kaoh-
siung Medical University Chung-Ho Memorial Hospital
(KMUH-IRB-980335).
Immunohistochemical staining and scoring
Paraffinized specimens were sectioned into thicknesses of
3e4 mm. After deparaffinization in xylene and rehydration
through a descending alcohol series, heat-induced epitope
retrieval was performed by heating sections to 121C for 8
minutes in pH 6.0 citrate buffer (Dako, Glostrup, Denmark).
The sections were then incubated with E-cadherin (dilution
1:150 for 30 minutes; Santa Cruz Biotechnology, TX, USA),
b-catenin (dilution 1:100 for 30 minutes; Santa Cruz
Biotechnology, Texas, USA), and p63 (dilution 1:100 for 30
minutes; Dako) antibodies according to the manufacturer
instructions. The DAKO REAL EnVision Detection kit (Dako)
was then applied for 30 minutes. The sections were
developed with 3,30-diaminobenzidine for 5 minutes and
counterstained with hematoxylin for 1 minutes. After
dehydration and mounting, semiquantitative analyses of
the expression of p63, E-cadherin, and b-catenin were
performed independently by two pathologists. In the case
of a discrepancy, both pathologists simultaneously rean-
alyzed the immunohistochemical slide and obtained a finalexpression in urothelial carcinomas in blackfoot disease-endemic
g/10.1016/j.kjms.2016.10.006
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immunoreactivity was used as a positive control for E-
cadherin, and cervical carcinoma tissue was used as the
positive control for b-catenin and p63 immunostainings.
Negative controls were performed by replacing the primary
antibody with a nonimmune serum.
The scores for p63, E-cadherin, and b-catenin were
obtained by multiplying the intensity and the percentage
of tumor cells according to a modified scoring system
[19e21]. The staining intensity was scored as follows: 0,
negative; 1, weak; 2, moderate; and 3, strong. For p63, the
nuclear staining of the tumor cells results was scored
using the following scale: 0,  10%; 1, 11e30%; 2, 31e50%;
and 3, > 50%. For E-cadherin and b-catenin, the percent-
age of cytoplasmic staining cells were scored using the
following scale: 0,  5%; 1, 6e25%; 2, 26e50%; and 3,
>50%. High expression of p63 and E-cadherin was defined
as a final score of  4.5. In addition, membranous b-cat-
enin stains were also evaluated independently. Therefore,
the b-catenin expression in tumor cells was considered as
normal expression if the final score for both cytoplasmic
and membrane stains were  4.5. However, reduced
membrane stain or cytoplasmic stain was considered as
aberrant expression. Three random fields in each slide
were examined at 200 and 400 magnification.
Statistical analysis
All statistical analyses were performed using the SPSS version
18.0 statistical software program (SPSS Inc., Chicago, IL,
USA). Ap value< 0.05was considered statistically significant.
The obtained data were analyzed by Chi-square tests.
Results
Of the 42 UC cases analyzed in this study, 20 were from
endemic areas of BFD, and 22 were from nonendemic areas
of BFD. Figure 1 and Tables 1 and 2 present the immuno-
histochemical results for p63, E-cadherin, and b-catenin in
the UC cases.
In p63 immunostaining, normal urothelium showed nu-
clear immunoreactivity with a mildly decreasing gradient
from basal to luminal cells, but the superficial umbrella
cells remained unstained [9]. High expression for p63 wasFigure 1. (A) Aberrant immunostaining of b-catenin in represent
disease, including reduced cytoplasmic and membranous expression
urothelial carcinoma cases in representative nonblackfoot disease
Please cite this article in press as: Chen Y-T, et al., Aberrant b-catenin
areas, Kaohsiung Journal of Medical Sciences (2016), http://dx.doi.ornoticed in 50.0% (10 of 20) of the UC cases in endemic areas
of BFD and in 45.5% (10 of 22) of the UC cases in non-
endemic areas of BFD. However, p63 expression did not
significantly differ between BFD and non-BFD areas
(p> 0.99). Additionally, p63 expression showed no corre-
lations with sex, age, grade, invasiveness, or recurrence.
The E-cadherin immunostaining results for normal uro-
thelia showed immunoreactivity in the cell membrane [22].
In all 20 UC cases in BFD endemic areas, membranous
staining intensity decreased as cytoplasmic expression of E-
cadherin increased. Cytoplasmic E-cadherin expression was
high in 20.0% (4 of 20) cases and low in 80.0% (16 of 20)
cases. However, in the UC cases in non-BFD areas, cyto-
plasmic staining was high in 22.7% (5 of 22) and low in 77.3%
(17 of 22). This trend did not significantly differ between
BFD and non-BFD areas (p> 0.99). Additionally, E-cadherin
expression showed no significant associations with other
clinicopathologic parameters.
In b-catenin immunostaining, normal urothelia showed
immunoreactivity in the cell membrane [22]. All 20 UC
cases from BFD areas showed cytoplasmic expression or
reduced membranous expression. Of the UC cases from the
non-BFD area, 54.5% (12 of 22) cases showed normal b-
catenin membranous expression and 45.5% (10 of 22) cases
showed aberrant staining. The b-catenin staining patterns
was significantly correlated between the UC from BFD and
non-BFD areas (pZ 0.001). Expressions of b-catenin were
also significantly associated with tumor sites (pZ 0.044).
All bladder UC cases showed aberrant b-catenin expression.
Discussion
Arsenic is an environmental pollutant and a well-known
cause of physical toxicity leading to tumorigenesis. In the
preindustrial era, local residents in southern areas of
Taiwan had a higher than normal risk of skin cancer. BFD
caused by oral intake of contaminated food or water was
also common [23]. Because of the unfavorable tumor phe-
notypes in patients in this area, patients with arsenic-
related genitourinary tract tumors had lower than normal
overall and cancer-specific survival [24,25]. Arsenic may
induce mitotic arrest, apoptosis, and cytotoxicity in human
urothelial cells [26] and is a suspected contributor to tumor
invasiveness and metastasis [27]. However, the effectsative urothelial carcinoma cases in endemic areas of blackfoot
, 200; (B) intact membranous immunostaining of b-catenin in
areas, 200.
expression in urothelial carcinomas in blackfoot disease-endemic
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Table 1 Immunohistochemical staining results for E-cadherin and p63 in urothelial carcinomas.
Parameters All p63 E-cadherin
High Low p* High Low p
All 42 20 (47.6) 22 (52.4) 6 (14.3) 31 (73.8)
Sex 0.749 >0.99
Male 27 (64.3) 12 (44.4) 15 (55.6) 6 (22.2) 21 (77.8)
Female 15 (35.7) 8 (53.3) 7 (46.7) 3 (20.0) 12(80.0)
Age (y) 0.757 0.477
67 23 (54.8) 10 (43.5) 13 (56.5) 6 (26.1) 17 (73.9)
<67 19 (45.2) 10 (62.5) 9 (37.5) 3 (15.7) 16 (84.2)
Site 0.526 0.867
Bladder 11 (26.2) 6 (54.5) 5 (45.5) 2 (18.2) 9 (81.8)
Kidney 24 (57.1) 12 (50.0) 12 (50.0) 5 (20.8) 19 (79.2)
Ureter 7 (16.7) 2 (28.6) 5 (71.4) 2 (28.6) 5 (71,4)
Tumor grade 0.738 0.406
Low 12 (27.0) 5 (41.7) 7 (58.3) 4 (33.3) 8 (66.7)
High 30 (73.0) 15 (50.0) 15 (50.0) 5 (18.1) 25 (81.9)
Invasion >0.99 0.699
Yes 12 (29.7) 6 (50.0) 6 (50.0) 3 (25.0) 9 (75.0)
No 30 (70.3) 14 (46.2) 16 (53.8) 6 (20.0) 24 (80.0)
Recurrence 0.354 >0.99
Yes 21 (54.1) 12 (57.1) 9 (42.9) 5 (23.8) 16 (76.2)
No 21 (45.9) 8 (38.1) 13 (61.9) 4 (19,0) 17 (81.0)
BFD area >0.99 >0.99
Yes 20 (48.6) 10 (50.0) 10 (50.0) 4 (20.0) 16 (80.0)
No 22 (51.4) 10 (45.5) 12 (54.5) 5 (22.7) 17 (77.3)
Data are presented as n (%).
BFDZ blackfoot disease.
* Statistically significant (p< 0.05).
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E-cadherin, and b-catenin expressions in carcinogenesis
remain unclear.
Since mutations of the p63 gene in human cancer are
rare, its biofunctions may include tumor suppression and
oncogenic activity in various cancer types [7]. Unlike the
tumor suppressor protein p53, which is only detectable in
epithelial cells under stress conditions, p63 is expressed in
the nuclei of mature epithelial cells in the basal layer under
normal conditions and is overexpressed in many cancers.
The experimental results in this study showed that arsenic
does not significantly affect clinicopathologic factors. The
effect of arsenic on p63 protein expression did not signifi-
cantly differ between BFD and non-BFD areas. A previous
study reported that arsenic exposure induced malignant
transformation of human epithelial stem/progenitor cells
into cancer stem-like phenotypes. An early loss of p63 also
resulted from arsenic exposure but was later reversed [11].
The p63 protein exists as multiple isoforms with opposing
functions [9]. This complexity indicates that p63 has a self-
renewal function, which explains the variable protein
levels. Arsenic exposure may impair this function.
The E-cadherin gene is located on chromosome 16q22.1,
and its encoded protein is expressed in many normal
epithelial tissues as a calcium-dependent cellecell adhesion
glycoprotein. E-cadherin is critical for the formation and
maintenance of adherent junctions of epithelial cellecell
interaction. Loss of E-cadherin protein or mutation of thisPlease cite this article in press as: Chen Y-T, et al., Aberrant b-catenin
areas, Kaohsiung Journal of Medical Sciences (2016), http://dx.doi.orgene may cause human cancer cell proliferation, dediffer-
entiation, invasiveness, and even metastasis [28]. Immuno-
histochemical analysis of normal tissues revealed E-cadherin
protein in cellular membranes. In UC, loss of membranous E-
cadherin and aberrant cytoplasmic or nuclear immunore-
activity are associated with tumor recurrence and poor
prognosis [29].
Studies show that arsenic silences the E-cadherin gene in
patients with nasopharyngeal cancer [30]. Arsenic also has
anticancer effects in patients with liver, breast, and cer-
vical tumors, and it induces a mesenchymal-to-epithelial
transition by reducing cell migration and invasion [27,31].
Our analysis of clinicopathologic parameters showed no
significant difference in E-cadherin. The E-cadherin gene
polymorphism, “geneeenvironment” interaction, and can-
cer types should be considered. The effects of arsenic
exposure on protein expression may vary in different tumor
types [32].
Previous studies have reported the presence of b-cat-
enin in the plasma membrane of normal epithelial cells.
The intracellular domain of E-cadherin contains a highly
phosphorylated region vital to b-catenin binding, which
prevents b-catenin nuclear localization. This functional
complex maintains an adherent junction between normal
epithelium [33]. Therefore, loss of the E-cadherineb-cat-
enin complex is also an important contributor to the pro-
gression, metastasis, and poor prognosis of many epithelial
malignancies, including genitourinary tract tumor [34]. Inexpression in urothelial carcinomas in blackfoot disease-endemic
g/10.1016/j.kjms.2016.10.006
Table 2 Immunohistochemical staining results for b-cat-
enin in urothelial carcinomas.
Parameters All b-catenin
Normal Aberrant p
All 42 10 (23.8) 32 (76.2)
Sex 0.487
Male 27 (64.3) 7 (25.9) 20 (75.0)
Female 15 (35.7) 3 (20.0) 12 (80.0)
Age (y) >0.99
67 23 (54.8) 5 (21.7) 18 (78.3)
<67 19 (45.2) 5 (26.3) 14 (73.7)
Tumor site 0.044*
Bladder 11 (26.2) 0 (0) 11 (100)
Kidney 24 (57.1) 9 (37.5) 15 (62.5)
Ureter 7 (16.7) 1 (14.3) 6 (85.7)
Tumor grade 0.696
Low 12(28.6) 2 (16.7) 10 (83.3)
High 30 (71.4) 8 (26.7) 22 (73.3)
Invasion 0.233
Yes 12 (28.6) 1 (8.3) 11 (91.7)
No 30 (71.4) 9 (30.0) 21 (70.0)
Recurrence 0.719
Yes 21 (50.0) 6 (28.6) 15 (701.4)
No 21(50.0) 4 (19.0) 17 (81.0)
BFD area 0.001*
Yes 20 (47.6) 0 (0) 20 (100)
No 22 (52.4) 10 (45.5) 12 (54.5)
Data are presented as n (%).
BFDZ blackfoot disease.
* Statistically significant (p< 0.05).
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+ MODELUC, E-cadherin may inactivate Wnt/b-catenin signaling in
normal urothelium [35]. Aberrant expression of b-catenin
has been studied extensively, and its association with
advanced stages of UC and a poor outcome is well recog-
nized [36,37]. A literature review reveals only a few studies
that have discussed b-catenin expression in cancer patients
after arsenic-exposure. In arsenic-transformed endothelial
cells, neuroblastomal cells, and colorectal cells, the
epithelial-to-mesenchymal transition and tumorigenesis
promote angiogenesis by activating the b-catenin-based
signaling pathway [38]. Arsenic trioxide reduces b-catenin
levels in myeloma cell lines [39] and decreases b-catenin
activity in cervical cancer cells [27]. This study revealed
that compared with cases in non-BFD areas, cases in BFD
areas had a larger aberrant cytoplasmic accumulation of b-
catenin and a greater loss of membranous staining
compared with those in non-BFD areas. We suggest that, in
BFD-endemic areas, toxic substances such as arsenic can
induce b-catenin localization from membrane to cyto-
plasm, which can then cause functional alterations of b-
catenin. This effect has also been observed previously in
other tumors. Our results also found an association be-
tween b-catenin and tumor sites. Therefore, the effect of
arsenic on different urinary anatomic sites may vary due to
different exposure mechanisms. All bladder UC cases
showed aberrant b-catenin expression. The longer the
urothelium is exposed to urine, the more obvious the ef-
fects and toxicity of the chemical material.Please cite this article in press as: Chen Y-T, et al., Aberrant b-catenin
areas, Kaohsiung Journal of Medical Sciences (2016), http://dx.doi.orIn conclusion, this study found that aberrant b-catenin
expression is associated with tumor site and with UC in
endemic areas of BFD. Arsenic may participate in the b-
catenin pathway by causing aberrant immunoreactivity.
However, its interactions and molecular mechanisms in UC
need further study.References
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